Tirazone
(tirapazamine)Phase 3Small molecule
SanofiTirapazamine is used as a cancer treatment, particularly for head and neck cancers and cervical cancer, often combined with radiation therapy to make cancer cells more vulnerable to treatment.[1] Tirazone is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Tirazone is one of 52 small molecule programs targeting Liver Cancer. It is currently in Phase 3.
1
Indications
19
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
61 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Idamycin
PfizerApproved
Blenoxane
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Glucophage
EMD SeronoApproved
Alimta
SShawn Eagle
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Cancer3 trials
Non-Small Cell Lung Cancer3 trials
Cervical Cancer3 trials
Small Cell Lung Cancer2 trials
7 more indications
Advanced Malignant Solid Tumors1 trial
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
Completed·—·Phase 1·NCT00005078·44 enrolled
Rhabdomyosarcoma1 trial
Head and Neck Cancer1 trial
Primary Peritoneal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for tirapazamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]